Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

NCT05243329 is registered in ClinicalTrials.gov with Halucenex Life Sciences Inc. as lead sponsor.

NCT NCT05243329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05243329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Lead sponsor
Halucenex Life Sciences Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 3, 2022
Completion date
December 30, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post traumatic stress disorder, treatment resistant disorders